Javascript must be enabled to continue!
Phospho-proteomic analysis of CAR-T cell signaling following activation by antigen-presenting cancer cells
View through CrossRef
Abstract
Chimeric antigen receptors (CARs) are synthetic biomolecules comprised of an extracellular antigen recognition domain and intracellular signaling domains. When expressed in immune cells, CARs direct their host cells to kill diseased cells expressing the antigen recognized by the CAR. Although signaling pathways downstream of CAR activation control the cytotoxic function of CAR-expressing cells, phospho-proteomic studies of CAR signaling have been limited. Most approaches have used antibodies or soluble ligands, rather than cell-displayed antigens, to activate CAR signaling. Here, we demonstrate an efficient and cost-effective label-free phospho-proteomic approach to analyze CAR signaling in immune cells stimulated with antigen-presenting cancer cells. Following co-culture of CAR-T cells with cancer cells, we first preserve phospho-signaling by cross-linking proteins with formalin. Then, we use magnet-activated cell sorting (MACS) to isolate CAR-T cells from the co-culture. Validation experiments demonstrated that formalin fixation did not alter the phospho-proteome and that MACS achieved >90% CAR-T cell purity. Next, we compared the phospho-proteome in CAR-T cells stimulated with either CD19-expressing or non-CD19-expressing SKOV3 ovarian cancer cells. This analysis revealed that CAR signaling activated known pathways including the mitogen- activated protein kinases (MAPKs) ERK1/2. Bioinformatic approaches further showed that CAR activation induced other signaling pathways including the MAPK p38α, protein kinase A, and checkpoint kinase 1 (CHK1). Taken together, this work presents an easy and inexpensive method to better understand CAR immunotherapy by label-free phospho-proteomic analysis of CAR signaling in immune cells stimulated by antigen- presenting cancer cells.
Title: Phospho-proteomic analysis of CAR-T cell signaling following activation by antigen-presenting cancer cells
Description:
Abstract
Chimeric antigen receptors (CARs) are synthetic biomolecules comprised of an extracellular antigen recognition domain and intracellular signaling domains.
When expressed in immune cells, CARs direct their host cells to kill diseased cells expressing the antigen recognized by the CAR.
Although signaling pathways downstream of CAR activation control the cytotoxic function of CAR-expressing cells, phospho-proteomic studies of CAR signaling have been limited.
Most approaches have used antibodies or soluble ligands, rather than cell-displayed antigens, to activate CAR signaling.
Here, we demonstrate an efficient and cost-effective label-free phospho-proteomic approach to analyze CAR signaling in immune cells stimulated with antigen-presenting cancer cells.
Following co-culture of CAR-T cells with cancer cells, we first preserve phospho-signaling by cross-linking proteins with formalin.
Then, we use magnet-activated cell sorting (MACS) to isolate CAR-T cells from the co-culture.
Validation experiments demonstrated that formalin fixation did not alter the phospho-proteome and that MACS achieved >90% CAR-T cell purity.
Next, we compared the phospho-proteome in CAR-T cells stimulated with either CD19-expressing or non-CD19-expressing SKOV3 ovarian cancer cells.
This analysis revealed that CAR signaling activated known pathways including the mitogen- activated protein kinases (MAPKs) ERK1/2.
Bioinformatic approaches further showed that CAR activation induced other signaling pathways including the MAPK p38α, protein kinase A, and checkpoint kinase 1 (CHK1).
Taken together, this work presents an easy and inexpensive method to better understand CAR immunotherapy by label-free phospho-proteomic analysis of CAR signaling in immune cells stimulated by antigen- presenting cancer cells.
Related Results
Complex Collision Tumors: A Systematic Review
Complex Collision Tumors: A Systematic Review
Abstract
Introduction: A collision tumor consists of two distinct neoplastic components located within the same organ, separated by stromal tissue, without histological intermixing...
Functional Diversification and Dynamics of CAR-T Cells in B-ALL Patients
Functional Diversification and Dynamics of CAR-T Cells in B-ALL Patients
Chimeric antigen receptor-engineered (CAR)-T cell therapy represents one of the most promising strategies of cancer treatment, and the function and persistence of CAR-T cells in vi...
MARS-seq2.0: an experimental and analytical pipeline for indexed sorting combined with single-cell RNA sequencing v1
MARS-seq2.0: an experimental and analytical pipeline for indexed sorting combined with single-cell RNA sequencing v1
Human tissues comprise trillions of cells that populate a complex space of molecular phenotypes and functions and that vary in abundance by 4–9 orders of magnitude. Relying solely ...
Selinexor Reduces the Immunosuppressive Properties of Macrophages and Synergizes with CD19 CAR-T Cells Against B-Cell Lymphoma
Selinexor Reduces the Immunosuppressive Properties of Macrophages and Synergizes with CD19 CAR-T Cells Against B-Cell Lymphoma
Background: CD19 chimeric antigen receptor (CAR)-T cell therapy has achieved high response rates in patients with B-cell lymphoma (BCL). However, treatment failure and relapse can ...
Abstract 1777: A non-signaling CAR for gamma-delta (γδ) T cells to preserve healthy tissues
Abstract 1777: A non-signaling CAR for gamma-delta (γδ) T cells to preserve healthy tissues
Abstract
Chimeric antigen receptor T cell (CAR-T) therapy for B cell leukemias and lymphomas have shown remarkable responses in the clinic. However, the elimination ...
Abstract 1427: IL6 trans-signaling robustly promotes the expansion and antitumor activity of CAR T cells
Abstract 1427: IL6 trans-signaling robustly promotes the expansion and antitumor activity of CAR T cells
Abstract
Chimeric antigen receptor T (CAR T) cell immunotherapy targeting CD19 positive B cells malignancies induces promising clinical remissions. However, the trea...
Abstract 1490: Dual chlorotoxin and methylguanine methyltransferase γδ-T cells for drug resistant immunotherapy of glioblastoma multiforme
Abstract 1490: Dual chlorotoxin and methylguanine methyltransferase γδ-T cells for drug resistant immunotherapy of glioblastoma multiforme
Abstract
While recent advances in immunotherapies have shown promise in extracranial tumors, Glioblastoma Multiforme (GBM) has remained impervious to these advances ...
PARP1 inhibition sensitizes AML to CD123 CAR-NK cells via immunophenotypic remodeling
PARP1 inhibition sensitizes AML to CD123 CAR-NK cells via immunophenotypic remodeling
Abstract
Background:Acute myeloid leukemia (AML) is an aggressive hematologic malignancy driven by leukemic stem cells (...

